TY - JOUR
T1 - In utero exposure to steroid contraceptives and survival during infancy
AU - Gray, Ronald H.
AU - Pardthaisong, Tieng
N1 - Funding Information:
Street, Baltimore, MD 21205 Support fof this study was provided by grant 830-0590 from the Ford Foundation, grant 84089 from the World Health Organization, and grant 3221-A from FamBy Health international The authors acknowledge Dr Edwin McDaniei for providing access to family planning clinic records, Dr Areeda Chandacham for clinical examination of children, Sukhon Songsattaga for supervision of field work, and Damkerng Chamnaca for computing and statistical support.
PY - 1991/10/15
Y1 - 1991/10/15
N2 - A cohort study was conducted in Chiang Mai, northern Thailand, in 1,431 children of women who had used the injectable contraceptive Depo-Provera® (The Upjohn Company, Kalamazoo, Michigan), 565 children of women who had used oral contraceptives during pregnancy, and a group of 2,307 control infants with no hormonal contraceptive exposures. In follow-up interviews, information was obtained on stillbirths and deaths. Cause of death was ascertained by interview, death certificate, or medical record, and underlying causes of death were ascribed by a panel. The children exposed in utero to Depo-Provera had higher neonatal and infant mortality rates (44.3 and 62.9 per 1,000 live births, respectively) than did the controls (19.8 and 29.1 per 1,000 live births). Mortality in infants exposed in utero to oral contraceptives was intermediate between that in the other two groups. Adjustment by logistic regression showed no significantly increased risk of mortality among infants exposed to oral contraceptives, but the odds ratio for death was significantly increased with Depo-Provera exposures due to accidental pregnancy (odds ratio (OR) = 1.8 (95% confidence interval (CI) 1.1-3.0) for neonatal deaths; OR = 2.0 (95% Cl 1.3-3 2) for infant deaths). Adjustment for low birth weight reduced the risks, suggesting that low birth weight may act as an intermediate determinant of Depo-Provera-associated mortality. Among the accidental pregnancies with Depo-Provera, there was a relation between shorter injection-to-conception intervals, when maternal blood levels of the drug are high, and an increased risk of mortality. The odds ratios for neonatal mortality were 2.5 (95% CI 1.1-5.7), 2.1 (95% Cl 1.0-4.6), and 0.9 (95% CI 0.4-2.4) for injection-to-conception intervals of ≤4, 5-8, and ≥9 weeks, respectively. Adjustment for low birth weight reduced these risks. Chi-square tests for trend were highly significant. Similar associations were also observed between DepoProvera accidental pregnancies and risks of low birth weight. Thus, infants from accidental pregnancies that occur 1-2 months after a 150-mg Depo-Provera injection may be at increased risk for low birth weight and death However, the attributable risk is low, because such pregnancies are uncommon.
AB - A cohort study was conducted in Chiang Mai, northern Thailand, in 1,431 children of women who had used the injectable contraceptive Depo-Provera® (The Upjohn Company, Kalamazoo, Michigan), 565 children of women who had used oral contraceptives during pregnancy, and a group of 2,307 control infants with no hormonal contraceptive exposures. In follow-up interviews, information was obtained on stillbirths and deaths. Cause of death was ascertained by interview, death certificate, or medical record, and underlying causes of death were ascribed by a panel. The children exposed in utero to Depo-Provera had higher neonatal and infant mortality rates (44.3 and 62.9 per 1,000 live births, respectively) than did the controls (19.8 and 29.1 per 1,000 live births). Mortality in infants exposed in utero to oral contraceptives was intermediate between that in the other two groups. Adjustment by logistic regression showed no significantly increased risk of mortality among infants exposed to oral contraceptives, but the odds ratio for death was significantly increased with Depo-Provera exposures due to accidental pregnancy (odds ratio (OR) = 1.8 (95% confidence interval (CI) 1.1-3.0) for neonatal deaths; OR = 2.0 (95% Cl 1.3-3 2) for infant deaths). Adjustment for low birth weight reduced the risks, suggesting that low birth weight may act as an intermediate determinant of Depo-Provera-associated mortality. Among the accidental pregnancies with Depo-Provera, there was a relation between shorter injection-to-conception intervals, when maternal blood levels of the drug are high, and an increased risk of mortality. The odds ratios for neonatal mortality were 2.5 (95% CI 1.1-5.7), 2.1 (95% Cl 1.0-4.6), and 0.9 (95% CI 0.4-2.4) for injection-to-conception intervals of ≤4, 5-8, and ≥9 weeks, respectively. Adjustment for low birth weight reduced these risks. Chi-square tests for trend were highly significant. Similar associations were also observed between DepoProvera accidental pregnancies and risks of low birth weight. Thus, infants from accidental pregnancies that occur 1-2 months after a 150-mg Depo-Provera injection may be at increased risk for low birth weight and death However, the attributable risk is low, because such pregnancies are uncommon.
KW - Contraceptive agents, contraceptives, oral, fetal death
KW - Infant mortality
KW - Infant, low birth weight
KW - Medroxyprogesterone
UR - http://www.scopus.com/inward/record.url?scp=0025721814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025721814&partnerID=8YFLogxK
U2 - 10.1093/oxfordjournals.aje.a116153
DO - 10.1093/oxfordjournals.aje.a116153
M3 - Article
C2 - 1835283
AN - SCOPUS:0025721814
SN - 0002-9262
VL - 134
SP - 804
EP - 811
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
IS - 8
ER -